Collagenase From Vibrio alginolyticus Cultures

Abstract

Purpose The purpose of this study is to examine the activity of collagenase from cultures of Vibrio alginolyticus as in vitro as in biological samples and to evaluate clinical perspectives of this product about the treatment of fibroproliferative diseases like Dupuytren's contracture. Methods The experimental part of the study has been divided in 2 stages. In the first stage, the collagenase has been produced in laboratory, assessing its purity, verifying the in vitro degradation of collagen by the enzyme and measuring the size of the fragments; in the second part, an experimental injection into samples of fibrous cord typical of Dupuytren's disease has been performed in vitro. For the injection we used only collagenase, or collagenase after having subjected them to 2 types of mechanical stress or a collagenase combined with ethylenediamine tetra-acetic acid. Considering that the human samples have been treated in vitro, our institution does not require a specific informed consent. Results It appeared evident that the collagenase obtained from Vibrio alginolyticus (nonpathogenic bacterium) is highly pure (>98%) and does not contain nonspecific protease. The collagenase from Vibrio alginolyticus therefore has an excellent degradative capacity against the collagen and this activity takes on a dose- and time-dependent behavior. The collagenase from Vibrio alginolyticus does not act negatively on cell survival and collagen peptides obtained may provide a better proliferative stimulus compared to controls. Conclusions The collagenase from Vibrio alginolyticus, given its obvious ability in vitro and biological samples, could be an option in the nonsurgical treatment of Dupuytren's disease. Level of evidence Level III, therapeutic.

A Quorum-Sensing Inhibitor Strain of Vibrio alginolyticus Blocks Qs-Controlled Phenotypes in Chromobacterium violaceum and Pseudomonas aeruginosa

“…Although some may be considered pathogens to aquatic animals and humans [88], V. alginolyticus strains are recognized to be typical coral symbiotic bacteria [60], which are also frequently present in healthy fish, shrimps, and mollusks [89] and whose biotechnological potential has been used for collagenase production in the clinic [90]. With regard to the QSI potential of V. alginolyticus , although Wang et al [91] have reported that the diketopiperazine cyclo (Leu-Pro) produced by a strain of this species isolated from sea anemones is capable of inhibiting mussel fouling, its QSI capacity was not tested.…”

In Vitro Study of a Novel Vibrio alginolyticus-Based Collagenase for Future Medical Application

“…Due to its low metabolic activity against fibronectin and decorin, the primary utility of Vibrio collagenases depends on their capability to perform the careful eradication of necrotic tissue [ 44 , 50 ] with only minor damage to the periwound healthy tissues [ 51 , 52 ]. V. collagenase has been established to be valuable and adequate as a debriding instrument and is being recommended for pharmaceutical use [ 53 ]. The value and accordance of collagenase have been a recurring theme in the literature between batches and manufacturers [ 54 ].…”

Vibrio Proteases for Biomedical Applications: Modulating the Proteolytic Secretome of V. alginolyticus and V. parahaemolyticus for Improved Enzymes Production

“…The secreted collagenase from V. alginolyticus is being successfully applied for pharmaceutical uses [30] and references therein] that exhibits limited non-specific proteolytic activity, which reduces side effects due to digestion of healthy tissues [31]. Therefore, such enzyme, which is industrially produced by autologous expression, has proven to be useful and effective as debriding agent for medical uses (i.e., ointments and other devices).…”